Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Harnessing Signal Transduction to Optimize Outcomes in Kidney Cancer

Release Date: October 21, 2008| Expiration Date: October 21, 2009
Sep 26, 2008, Chicago, IL

Lecture Overview

The Harnessing Signal Transduction to Optimize Outcomes in Kidney Cancer activity will provide oncologists with a clinically relevant overview of the current understanding of tumor and microenvironment cell biology, with applications to the treatment of kidney cancer. This information will be linked to applications in the clinical management of these patients. This educational activity is directed primarily toward medical oncologists interested in the treatment of cancer. Physician assistants, nurses, fellows, pharmacists, and other health care professionals who are interested in the treatment of cancer are also invited to participate.

Upon completion of this educational activity, you should be able to:

    • Evaluate the rationale for targeting the tumor microenvironment and signal transduction in cancer therapy
    • Describe the roles of angiogenesis/vasculogenesis and mTOR signaling in the pathophysiology of renal cell carcinoma
    • Describe the clinical efficacy and safety of antiangiogenic agents and mTOR inhibitors in advanced renal cell carcinoma

    Instructions for Participation

    1. Read the following information before beginning the educational activity.
    2. Complete the pre-test.
    3. View and study all Flash video presentations.
    4. Complete the CME test.
    5. Answer the evaluation questions.
    • CME credit will be granted for online participation only.

    Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

    Disclosure Policy

    It is the policy of Physicians' Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians' Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

    These persons involved in the influence or control of content for the presentations from Harnessing Signal Transduction to Optimize Outcomes in Kidney Cancer symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

    Gary Hudes, MD
    Paid Consultant/Advisory Board – Genentech, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., and Wyeth Pharmaceuticals.

    Thomas Hutson, DO, PharmD, FACP
    Research Funding – Amgen, GlaxoSmithKline, Pfizer Inc., Wyeth Pharmaceuticals
    Paid Consultant/Advisory Board – Bayer Pharmaceuticals Corporation, Pfizer Inc., Wyeth Pharmaceuticals
    Speaker’s Bureau – Bayer Pharmaceuticals Corporation, Pfizer Inc., Wyeth Pharmaceuticals

    Eric Jonasch, MD
    Research Funding – Genentech, Inc.
    Paid Consultant/Advisory Board – Agennix, Inc., Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals, Inc., Pfizer Inc., Wyeth Pharmaceuticals
    Speaker’s Bureau – Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals, Inc., Pfizer Inc., Wyeth Pharmaceuticals

    This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

    Software Requirements

    The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

    If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

    PC Users
    If you need to upgrade your Web browser, follow one of the links listed below:

    Macintosh Users
    Compatible Web browsers include

    Disclaimer

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the faculty and Physicians' Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

    Please consult full prescribing information for any drugs or procedures discussed within.

    Privacy Policy

    Physicians' Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

    All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

    ©Copyright 2008 by Physicians’ Education Resource.

    All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

    All correspondence should be directed to:
    Editor, Harnessing Signal Transduction to Optimize Outcomes in Kidney Cancer
    Physicians' Education Resource
    3500 Maple Ave.
    Suite 700
    Dallas, TX 75219
    Phone: (214) 367-3400
    Fax: (214) 367-3304
    E-mail: editor@pergrouplp.com

Educational Grants

An educational grant for this activity was provided by:


  1. Novartis Oncology